Drug intelligence / Profile preview

eliapixant

Development stage: Discontinued
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Eliapixant (formerly known as BAY 181708 or BAY-1817080) is a small molecule purinergic P2X3 receptor antagonist developed by Bayer. It was investigated for the treatment of persistent cough, neuropathic pain, overactive bladder, and endometriosis. The drug belongs to several chemical classes including amides, fluorocarbons, phenyl ethers, pyrimidines, and thiazoles. Its mechanism of action involves antagonism of the P2X3 receptor—a target implicated in sensory nerve signaling related to cough and pain[1].

Other names: eliapixantBAY 1817080BAY1817080BAY-1817080

Targets

P2X3 (P2X purinoceptor 3)

Beyond the preview

Go deeper on eliapixant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eliapixant.

Explore the full profile